ArticleFuture science OA2025
Analysis of burden of liver cancer by GBD 2021.
Article in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study used the Global Burden of Disease (GBD) 2021 database to analyze and summarize the global disease burden and changing trends of liver cancer, which has strong public health reference value. RESEARCH DESIGN AND
methodsThe data for this study is drawn from the GBD 2021 study. In the analysis, we conducted a detailed stratification based on gender, 20 age groups, 21 GBD regions, 204 countries and territories, and 5 SDI quintiles. This study aims to explore the liver cancer burden of age-standardized prevalence rates (ASPR), incidence rates, death rates (ASMR), and disability-adjusted life years (ASDR).
resultsIn 2021, liver cancer continued to impose a substantial global burden. Although the global burden of liver cancer is declining overall, there are marked regional differences in the scale of reduction. Incidence of liver cancer varies markedly across regions and sexes within each age group, with older people bearing a disproportionately high burden, especially among males in high SDI regions and low-middle SDI regions. The declining global incidence of liver cancer among both genders from 2022 to 2040.
conclusionsThese patterns highlighted the necessity for focused public health measures and management plans to tackle the inequalities in liver cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.